Sputnik V Covid vaccine 91.6% effective in Phase-III trial: Peer-reviewed data4 min read . Updated: 02 Feb 2021, 06:18 PM IST
- Russia's Gamaleya Institute publishes peer-reviewed results of Sputnik V Covid-19 vaccine in the Lancet medical journal
- The vaccine was found equally effective in people aged above 60, shows trial data
Russia's Sputnik V vaccine is 91.6 percent effective against symptomatic Covid-19 in Phase-III trial, according to peer-reviewed results published in The Lancet medical journal on Tuesday.
Select your Category